Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that its clinical facility in Mexico City has begun recruiting patients for Group Two of its ongoing human clinical study of the Ocumetics Lens, a next-generation accommodating intraocular lens designed to potentially eliminate the need for corrective lenses. This move marks a significant step forward in the company's clinical development, expanding beyond the safety-focused Group One study to assess both safety and vision performance at near and distance.
The Group Two study will evaluate the latest-generation Ocumetics Lens, which incorporates the company's most recent design advancements, and will be implanted using an enhanced delivery system. Unlike Group One, which focused solely on safety, this phase will measure the lens's ability to provide clear vision across a range of distances, a key differentiator for the technology. The Mexico City facility, which successfully conducted Group One surgeries in Fall 2025, has started identifying and recruiting eligible patients, with surgeries targeted for Fall 2026.
Dean Burns, President and CEO of Ocumetics, expressed enthusiasm about the progress: "We are extremely excited to begin the process of moving into our larger Group Two study. Commencement of this study represents another important milestone in the continued clinical development of the Ocumetics Lens. Recruiting will be completed soon and we will schedule surgical dates shortly thereafter."
A notable aspect of this announcement is the approaching 12-month follow-up for Group One patients, which will provide longer-term clinical data on safety and performance. Burns highlighted the importance of this milestone: "We are particularly excited to reach the 12-month milestone for our Group One patients, which will provide an important body of longer-term clinical data as we continue to advance the Ocumetics Lens. At the same time, the Group Two study represents an important step forward as we introduce our next-generation Ocumetics Lens together with our next-generation lens delivery system. This combination represents the continued evolution of our technology and our commitment to developing a truly differentiated solution for patients seeking improved vision across a broader range of distances."
The Group One clinical outcomes met and exceeded the company's expectations regarding safety, performance, and handling, providing a strong foundation for the next phase. Patients from Group One continue to be followed, and their 12-month data will be crucial in validating the long-term benefits of the lens.
Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions. Its flagship product, the Ocumetics Lens, is designed to fit within the natural lens compartment of the eye, allowing the eye's natural muscle activity to shift focus from distance to near, potentially providing clear vision at all distances without glasses or contact lenses. The company is currently in the first-in-human early feasibility study phase, and this new recruitment marks a pivotal expansion in its clinical trial program.
